ID: h-var-ffacbbd9f1
Hypothesis

NAD+-Dependent Upregulation of MCT1 Expression to Restore Neuronal Ketone Metabolism

This hypothesis proposes that NAD+ precursor supplementation can restore neuronal ketone body utilization by activating SIRT1-mediated upregulation of MCT1 (monocarboxylate transporter 1).
🧬 SLC16A1 (MCT1)🩺 metabolomics🎯 Composite 38%💱 $0.46▲15.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 4 oppose
✓ All Quality Gates Passed

🧪 Overview

This hypothesis proposes that NAD+ precursor supplementation can restore neuronal ketone body utilization by activating SIRT1-mediated upregulation of MCT1 (monocarboxylate transporter 1). In neurodegenerative conditions, chronic PARP1 activation depletes cellular NAD+ pools, leading to reduced SIRT1 activity and subsequent downregulation of MCT1 expression. This creates a metabolic catastrophe where neurons lose their ability to efficiently transport and utilize ketone bodies as an alternative energy source when glucose metabolism is compromised. By supplementing with NAD+ precursors (such as nicotinamide riboside or NMN), cellular NAD+ levels are restored, reactivating SIRT1 deacetylase activity. SIRT1 then deacetylates key transcription factors and histone proteins at the SLC16A1 promoter region, enhancing MCT1 gene expression. The resulting increase in MCT1 protein levels on neuronal membranes restores efficient ketone body uptake, providing neurons with a critical alternative fuel source that can bypass defective glycolytic pathways.

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["DNA Single-Strand Breaks<br/>Oxidative Stress in AD"]
    B["PARP1 Hyperactivation<br/>PAR Polymer Synthesis"]
    C["NAD+ Depletion<br/>40-60% Loss in AD"]
    D["SIRT1 Inactivation<br/>Deacetylase Impaired"]
    E["PGC1alpha Inactivation<br/>Mitochondrial Biogenesis Loss"]
    F["Energy Failure<br/>Neuronal Death"]
    G["PARP1 Inhibitor<br/>Olaparib/Veliparib"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    G -.->|"blocks"| B
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7

⚖️ Evidence

⚖️ Evidence Matrix4 supports4 contradicts
Supports
Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
Supports
NMN administration in 5xFAD mice restores cerebral NAD+ levels, improves mitochondrial function, and reduces amyloid plaque burden
Supports
Human trials of NR in older adults demonstrate safe NAD+ boosting and improvements in mitochondrial biomarkers in blood
Supports
SIRT3 deacetylase activity declines in AD brain, leading to hyperacetylated SOD2 and increased oxidative stress
Contradicts
NAD+ repletion in aged humans shows peripheral effects but unclear brain benefits - no direct CNS NAD+ measurement
Contradicts
PARP1 knockout mice show no protection against AD-like pathology - genetic deletion does not prevent amyloid deposition in APP/PS1 mice
Contradicts
PARP1 as primary NAD+ consumer is disputed - relative contributions of PARP1, SIRT1, SIRT2, CD38 vary by cell type
Contradicts
NMN supplementation studies use supraphysiological doses - mouse studies require doses unlikely achievable in humans
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SLC16A1

No curated PDB or AlphaFold mapping for SLC16A1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SLC16A1 (MCT1) from GTEx v10.

Spinal cord cervical c-119.7 Caudate basal ganglia15.6 Hippocampus15.5 Putamen basal ganglia14.6 Substantia nigra13.5 Cerebellar Hemisphere12.6 Frontal Cortex BA912.0 Hypothalamus11.8median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SLC16A1 (MCT1) →

No DepMap CRISPR Chronos data found for SLC16A1 (MCT1).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0026
Events (7d)
1
Price History
▲15.1%

💾 Resource Usage

LLM Tokens
38,010
$0.1140
Total Cost
$0.1140
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.